Conference Coverage
VIDEO: Progressive MS trial failures provide lessons for future success
Findings last year from the ORATORIO trial showed for the first time that a pharmaceutical agent – ocrelizumab – was effective for slowing the...
Dr. Lublin reported receiving research support and/or serving as a consultant for many companies marketing MS drugs, including Biogen, Genentech, and Novartis.
